SEPT9_v1 Up-regulates Hypoxia-inducible Factor 1 by Preventing Its RACK1-mediated Degradation

Sharon Amir, Ruoxiang Wang, Jonathan W. Simons, Nicola J. Mabjeesh

Journal of Biological Chemistry · 2009 · 66 citations · 31 references

DOIFull text

Open access

Concepts

Abstract

A critical mediator of the cellular response to hypoxia is hypoxia-inducible factor 1 (HIF-1). Increased levels of HIF-1α are often associated with increased tumor metastasis, therapeutic resistance, and poorer prognosis. We recently identified a novel interaction between HIF-1α and the mammalian septin family member, SEPT9_v1. Septins are a highly conserved family of GTP-binding cytoskeletal proteins that are implicated in multiple cellular functions, including cell division and oncogenesis. SEPT9_v1 binds and stabilizes HIF-1α protein and stimulates HIF-1 transcriptional activity. SEPT9_v1-HIF-1 activation promotes tumor growth and angiogenesis. The structural and functional relationships between SEPT9_v1 and HIF-1α were analyzed. We found that SEPT9_v1 binds specifically with HIF-1α but not with HIF-2α. The GTPase domain of SEPT9_v1 was identified as essential for HIF-1α binding. A GTPase domain-derived polypeptide, corresponding to amino acids 252–379, was able to disrupt HIF-1α-SEPT9_v1 interaction and to inhibit HIF-1 transcriptional activity. SEPT9_v1 also protected HIF-1α from degradation induced by HSP90 inhibition by preventing the interaction of HIF-1α with the RACK1 protein, which promotes its oxygen-independent proteasomal degradation. In conclusion, a new mechanism of oxygen-independent activation of HIF-1 has been identified that is mediated by SEPT9_v1 blockade of RACK1 activity on HIF-1α degradation. A critical mediator of the cellular response to hypoxia is hypoxia-inducible factor 1 (HIF-1). Increased levels of HIF-1α are often associated with increased tumor metastasis, therapeutic resistance, and poorer prognosis. We recently identified a novel interaction between HIF-1α and the mammalian septin family member, SEPT9_v1. Septins are a highly conserved family of GTP-binding cytoskeletal proteins that are implicated in multiple cellular functions, including cell division and oncogenesis. SEPT9_v1 binds and stabilizes HIF-1α protein and stimulates HIF-1 transcriptional activity. SEPT9_v1-HIF-1 activation promotes tumor growth and angiogenesis. The structural and functional relationships between SEPT9_v1 and HIF-1α were analyzed. We found that SEPT9_v1 binds specifically with HIF-1α but not with HIF-2α. The GTPase domain of SEPT9_v1 was identified as essential for HIF-1α binding. A GTPase domain-derived polypeptide, corresponding to amino acids 252–379, was able to disrupt HIF-1α-SEPT9_v1 interaction and to inhibit HIF-1 transcriptional activity. SEPT9_v1 also protected HIF-1α from degradation induced by HSP90 inhibition by preventing the interaction of HIF-1α with the RACK1 protein, which promotes its oxygen-independent proteasomal degradation. In conclusion, a new mechanism of oxygen-independent activation of HIF-1 has been identified that is mediated by SEPT9_v1 blockade of RACK1 activity on HIF-1α degradation. A key transcription factor for cells to respond and adapt to survive hypoxia is hypoxia-inducible factor-1 (HIF-1) 3The abbreviations used are: HIF-1, hypoxia-inducible factor 1; HSP90, heat shock protein 90; 17-AAG, 17-Allylamino-17-demethoxy-geldanamycin; HRE, hypoxia-response elements; ODDD, oxygen-dependent degradation domain; HLH, helix-loop-helix; PAS, Per-aryl hydrocarbon receptor nuclear translocator-Sim; HA, hemagglutinin; IP, immunoprecipitation; VHL, von Hippel-Lindau. 3The abbreviations used are: HIF-1, hypoxia-inducible factor 1; HSP90, heat shock protein 90; 17-AAG, 17-Allylamino-17-demethoxy-geldanamycin; HRE, hypoxia-response elements; ODDD, oxygen-dependent degradation domain; HLH, helix-loop-helix; PAS, Per-aryl hydrocarbon receptor nuclear translocator-Sim; HA, hemagglutinin; IP, immunoprecipitation; VHL, von Hippel-Lindau. (1.Semenza G.L. Sci. STKE. 2007; 2007: cm8Crossref PubMed Scopus (694) Google Scholar). HIF-1 target genes encode proteins involved in anaerobic metabolism (e.g. glycolytic enzymes and glucose transporters), angiogenesis (e.g. vascular endothelial growth factor), and erythropoiesis (e.g. erythropoietin) (2.Semenza G.L. Shimoda L.A. Prabhakar N.R. Novartis Found. Symp. 2006; 272: 2-16Crossref PubMed Scopus (2) Google Scholar). HIF-1 is a heterodimer and consists of a constitutively expressed subunit, HIF-1β, and an oxygen-regulated subunit, HIF-1α. HIF-1 transcriptional activity is directly affected by the abundance and stability of HIF-1α. HIF-1α protein expression is tightly regulated by O2 levels. Under normoxic conditions, human HIF-1α is hydroxylated by prolyl hydroxylases at two specific proline residues, Pro402 and Pro564 (3.Bruick R.K. McKnight S.L. Science. 2001; 294: 1337-1340Crossref PubMed Scopus (2066) Google Scholar, 4.Epstein A.C. Gleadle J.M. McNeill L.A. Hewitson K.S. O'Rourke J. Mole D.R. Mukherji M. Metzen E. Wilson M.I. Dhanda A. Tian Y.M. Masson N. Hamilton D.L. Jaakkola P. Barstead R. Hodgkin J. Maxwell P.H. Pugh C.W. Schofield C.J. Ratcliffe P.J. Cell. 2001; 107: 43-54Abstract Full Text Full Text PDF PubMed Scopus (2674) Google Scholar, 5.Ivan M. Kondo K. Yang H. Kim W. Valiando J. Ohh M. Salic A. Asara J.M. Lane W.S. Kaelin Jr., W.G. Science. 2001; 292: 464-468Crossref PubMed Scopus (3783) Google Scholar). The “proline” hydroxylated form of HIF-1α is recognized by von Hippel-Lindau tumor suppressor protein as part of a complex with E3 ubiquitin ligase activity that leads to ubiquitination and proteasome-dependent degradation of HIF-1α (6.Kallio P.J. Wilson W.J. O'Brien S. Makino Y. Poellinger L. J. Biol. Chem. 1999; 274: 6519-6525Abstract Full Text Full Text PDF PubMed Scopus (682) Google Scholar, 7.Cockman M.E. Masson N. Mole D.R. Jaakkola P. Chang G.W. Clifford S.C. Maher E.R. Pugh C.W. Ratcliffe P.J. Maxwell P.H. J. Biol. Chem. 2000; 275: 25733-25741Abstract Full Text Full Text PDF PubMed Scopus (909) Google Scholar). HIF-1 transcriptional activity is regulated by an additional mode of hydroxylation. Under normoxia, HIF-1α is also hydroxylated at asparagine residue 803 by factor inhibiting HIF-1α (FIH-1) leading to inhibition of CBP recruitment to the HIF-1α C-terminal transactivation domain (8.Mahon P.C. Hirota K. Semenza G.L. Genes Dev. 2001; 15: 2675-2686Crossref PubMed Scopus (1093) Google Scholar, 9.Lando D. Peet D.J. Gorman J.J. Whelan D.A. Whitelaw M.L. Bruick R.K. Genes Dev. 2002; 16: 1466-1471Crossref PubMed Scopus (1191) Google Scholar, 10.McNeill L.A. Hewitson K.S. Claridge T.D. Seibel J.F. Horsfall L.E. Schofield C.J. Biochem. J. 2002; 367: 571-575Crossref PubMed Scopus (168) Google Scholar). The hydroxylation reactions utilize O2 andα-ketoglutarate as substrates. Under hypoxia, HIF-1α is therefore not hydroxylated and becomes stabilized to heterodimerize with HIF-1β and to recruit co-factors such as CBP for transcriptional activation. In tumor cells HIF-1 can also be regulated and activated by other genetic factors such as oncogenes (Ras and phosphoinositide 3-kinase) or loss of tumor suppressors (VHL or PTEN) even under aerobic conditions. On another level of post-translational regulation, Liu et al. (11.Liu Y.V. Baek J.H. Zhang H. Diez R. Cole R.N. Semenza G.L. Mol. Cell. 2007; 25: 207-217Abstract Full Text Full Text PDF PubMed Scopus (383) Google Scholar) have recently identified RACK1 (receptor of activated protein kinase C 1) as a HIF-1α-interacting protein that competes with heat shock protein 90 (HSP90) for binding to HIF-1α and mediates O2- and prolyl hydroxylase/VHL-independent ubiquitination and proteasomal degradation (12.Bertout J.A. Patel S.A. Simon M.C. Nat. Rev. Cancer. 2008; 8: 967-975Crossref PubMed Scopus (1003) Google Scholar). We have recently described another novel activation pathway of HIF-1 under normoxia by a member of the mammalian septin family, SEPT9_v1 (septin 9 protein, variant 1) (13.Amir S. Wang R. Matzkin H. Simons J.W. Mabjeesh N.J. Cancer Res. 2006; 66: 856-866Crossref PubMed Scopus (57) Google Scholar). We discovered that SEPT9_v1 interacts with HIF-1α to prevent its ubiquitination and degradation. SEPT9_v1 protein activates HIF-1 transcriptional activity and increases tumor growth and angiogenesis in prostate cancer xenografts (13.Amir S. Wang R. Matzkin H. Simons J.W. Mabjeesh N.J. Cancer Res. 2006; 66: 856-866Crossref PubMed Scopus (57) Google Scholar). Similarly, Gonzalez et al. (14.Gonzalez M.E. Peterson E.A. Privette L.M. Loffreda-Wren J.L. Kalikin L.M. Petty E.M. Cancer Res. 2007; 67: 8554-8564Crossref PubMed Scopus (59) Google Scholar) have shown that high expression of SEPT9_v1 is also associated with accelerated growth kinetics and increased motility in human breast cancer cells. Therefore, we investigated the mechanisms of HIF-1 activation by SEPT9_v1. We found that SEPT9_v1 is involved in the regulation of the O2- and prolyl hydroxylase/VHL-independent degradation of HIF-1α, which is mediated by RACK1. Cell Culture and Hypoxia Treatment—Human prostate cancer PC-3 cells were cultured in RPMI 1640 as recommended by the American Type Culture Collection. Stably transfected PC-3 cells with SEPT9_v1 (PC-3-SEPT9_v1) or with the empty vector (PC-3-Neo) were designed and characterized previously (13.Amir S. Wang R. Matzkin H. Simons J.W. Mabjeesh N.J. Cancer Res. 2006; 66: 856-866Crossref PubMed Scopus (57) Google Scholar). PC-3 cells were infected with retroviral vector expressing either empty vector (PC-3-Puro) or shSEPT9_v1 (PC-3-shSEPT9_v1) as previously described (15.Amir S. Mabjeesh N.J. Cancer Biol. Ther. 2007; 6: 1926-1931Crossref PubMed Scopus (32) Google Scholar). HEK293 cells were maintained in Dulbecco's modified Eagle's medium. All of the media were supplemented with 10% fetal calf serum and antibiotics. The cells were cultured at 37 °C in a humidified atmosphere and 5% CO2 in air. For hypoxic exposure, the cells were placed in a sealed modular incubator chamber (Billups-Rothenberg, Del Mar, CA) flushed with 1% O2, 5% CO2, and 94% N2. Plasmids and Reagents—Human untagged-HIF-1α (GenBank™ accession number NM_001530), FLAG-HIF-1α, and FLAG-SEPT9_v1 (GenBank™ accession number AF189713) were previously constructed (13.Amir S. Wang R. Matzkin H. Simons J.W. Mabjeesh N.J. Cancer Res. 2006; 66: 856-866Crossref PubMed Scopus (57) Google Scholar). FLAG-tagged mutated and truncated forms of HIF-1α were constructed into p3XFLAG-Myc-CMV-25 (Sigma-Aldrich), whereas SEPT9_v1-Myc truncated forms were constructed into pcDNA4/Myc-His (A) (Invitrogen). Deletion and point mutations were performed by multiple overlapping PCRs using the specific primers as listed in Table 1. Human RACK1 (GenBank™ accession number NM_006098) was subcloned at HindIII/XbaI sites into pcDNA4/Myc-His (A) to produce RACK1-Myc-tagged fusion protein (Table 1). Hemagglutinin (HA)-HIF-2α expression vector was a generous gift from Dr. W. G. Kaelin (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA). All of the constructs were verified by DNA sequencing (Danyel Biotech, Rehovot, Israel).TABLE 1List of designed constructs and primes used in this studyGenePrimer sequencesFLAG-HIF-1constructs ΔHLHF: CCGCGCCCGCGGCCGCGATGGTTCTCACAGATGATGGTGR: CAGTTCTAGATTATCAGTTAACTTGATCCAAAGCTC ΔHLH/PASF: ACGTGCGGCCGCGTTTTCTACTCAGGACACAGATTTAGACTTGR: CAGTTCTAGATTATGAGTTAACTTGATCCAAAGCTCTGAG ΔPASAmino acids 1-85F: ACGTGCGGCCGCGATGGAGGGCGCCGGCGGCGCGAACGR: CCTGTACTGTCCTGTGGTGACTTGCATGTCATCTTCAATATCCAAATCAmino acids 298-826F: GATTTGGATATTGAAGATGACATGCAAGTCACCACAGGACAGTACAGGR: CAGTTCTAGATTATGAGTTAACTTGATCCAAAGCTCTGAG HLH/PASF: ACGTGCGGCCGCGATGGAGGGCGCCGGCGGCGCGAACGR: CAGTTCTAGATTAAGAATTCTTGGTGTTATATATGACAGTTG ΔODDDAmino acids 1-343F: ACGTGCGGCCGCGATGGAGGGCGCCGGCGGCGCGAACGR: GTTCTTCCTCAGGAACTGTAGTACTCACAACGTAATTCACACATACAmino acids 698-826F: GTATGTGTGAATTACGTTGTGAGTACTACAGTTCCTGAGGAAGAACR: CAGTTCTAGATTATGAGTTAACTTGATCCAAAGCTCTGAG DPMAmino acids 1-402 with P402AF: ACGTGCGGCCGCGATGGAGGGCGCCGGCGGCGCGAACGR: GTCTCCAGCGGCTGCGGCCAGCAAAGAmino acids 402-826F: CTTTGCTGGCCGCAGCCGCTGGAGACR: CAGTTCTAGATTATGAGTTAACTTGATCCAAAGCTCTGAGAmino acids 1-564 with P564AF: ACGTGCGGCCGCGATGGAGGGCGCCGGCGGCGCGAACGR: CATTGGGATATAGGCAGCTAACATCTCAmino acids 564-826 with P564AF: GAGATGTTAGCTGCCTATATCCCAATGR: CAGTTCTAGATTATGAGTTAACTTGATCCAAAGCTCTGAGSEPT9_v1-Myc constructs Full lengthF: ACTAAGCTTATGAAGAAGTCTTACTCAGGAGGCACGCGGACCR: ACGTTCTAGACATCTCTGGGGCTTCTGGCTCCTTCTCCTCC 1-251F: ACTAAGCTTATGAAGAAGTCTTACTCAGGAGGCACGCGGACCR: GTTCTAGAGTCGCCAACGCAGCTGGGAGC 252-586F: ACGTTCTAGACATCTCTGGGGCTTCTGGCTCCTTCTCCTCC in a new was from The were to HIF-1α and to RACK1 and to and to and and to SEPT9_v1 were previously (13.Amir S. Wang R. Matzkin H. Simons J.W. Mabjeesh N.J. Cancer Res. 2006; 66: 856-866Crossref PubMed Scopus (57) Google Scholar). were and cell and nuclear were as previously described N.J. D. H. Simons J.W. P. Cancer Cell. Full Text Full Text PDF PubMed Scopus Google Scholar). was using a protein The proteins were by and with as in the as described (13.Amir S. Wang R. Matzkin H. Simons J.W. Mabjeesh N.J. Cancer Res. 2006; 66: 856-866Crossref PubMed Scopus (57) Google Scholar, N.J. D. H. Simons J.W. P. Cancer Cell. Full Text Full Text PDF PubMed Scopus Google Scholar). of protein were in and cells were in or and were transfected with a of DNA or 1 of using to the activity was performed using the of the as previously described Ther. 2001; 8: PubMed Scopus Google Scholar, N.J. Simons J.W. H. Cancer Res. 2002; Google Scholar). of transfected were and under normoxic and hypoxic for activity was with using a the activity were to the of protein in in were in and 10% been transfected and and were to the The were at for at of the was and the was with the for at The were with protein for at The were with and were in for either transfected or in were with or at the in the at 37 °C under normoxic or hypoxic conditions. or the cells were with and to or in the are of or of was The are expressed as was used to between conditions. was using was at SEPT9_v1 HIF-1α but of previously that SEPT9_v1 interacts with HIF-1α protein to HIF-1 transcriptional activity (13.Amir S. Wang R. Matzkin H. Simons J.W. Mabjeesh N.J. Cancer Res. 2006; 66: 856-866Crossref PubMed Scopus (57) Google Scholar). the of HIF-1α-SEPT9_v1 we SEPT9_v1 or not also with HEK293 cells were with expression SEPT9_v1-Myc and The was performed in using to and The proteins from were by using and SEPT9_v1 were by corresponding interaction between the two proteins was that SEPT9_v1 not with HIF-2α. the interaction between HIF-1α and SEPT9_v1 proteins was under normoxia under hypoxia (13.Amir S. Wang R. Matzkin H. Simons J.W. Mabjeesh N.J. Cancer Res. 2006; 66: 856-866Crossref PubMed Scopus (57) Google we that hydroxylation of the proline and the oxygen-dependent degradation domain of HIF-1α the We therefore designed and point mutations in two proline and the interaction with SEPT9_v1 the protein expression level of HIF-1α was the HIF-1α of the amino the proline with SEPT9_v1 protein in a as the HIF-1α The that proline proline is for of SEPT9_v1 to HIF-1α and to HIF-1 that activation of HIF-1 by SEPT9_v1 is on the part acids and the GTP-binding acids of was for the interaction (13.Amir S. Wang R. Matzkin H. Simons J.W. Mabjeesh N.J. Cancer Res. 2006; 66: 856-866Crossref PubMed Scopus (57) Google Scholar). in a of SEPT9_v1 constructs were designed to the domain of SEPT9_v1 that binds to HIF-1α constructs were with HIF-1α in HEK293 cells and to an The C-terminal part of SEPT9_v1 acids of the conserved GTPase domain to HIF-1α protein, whereas the part acids not with HIF-1α of the C-terminal part that amino acids were to to HIF-1α we be able to with interaction and to HIF-1 activity. HEK293 cells were transfected with in the of HIF-1α and SEPT9_v1. of HIF-1α protein expression and a inhibition of HIF-1α with SEPT9_v1 of also to a of HIF-1 transcriptional activity by under normoxia and under were also in PC-3 cells not the domain identified of SEPT9_v1 is able to disrupt the complex and is of inhibiting HIF-1 transcriptional activity. The of HIF-1α for the with the domain of HIF-1α that interacts with a number of FLAG-tagged HIF-1α constructs were designed as in SEPT9_v1 and HIF-1α constructs were expressed in HEK293 cells and to an with the HIF-1α proline HIF-1α was not for the interaction with SEPT9_v1 the that HIF-1α domain with whereas other HIF-1α the domain not with SEPT9_v1 that the which is of the essential for with HIF-1β, is also for the interaction with SEPT9_v1. SEPT9_v1 to HIF-1α from have shown previously that SEPT9_v1 interacts with HIF-1α and its ubiquitination (13.Amir S. Wang R. Matzkin H. Simons J.W. Mabjeesh N.J. Cancer Res. 2006; 66: 856-866Crossref PubMed Scopus (57) Google Scholar). We investigated the mechanism of HIF-1α or by SEPT9_v1. that SEPT9_v1 not with the of HIF-1α and that the interaction is not by proline we for regulation other the degradation The protein, RACK1 interacts with HIF-1α and competes with HSP90 to HIF-1α ubiquitination and degradation that is of (11.Liu Y.V. Baek J.H. Zhang H. Diez R. Cole R.N. Semenza G.L. Mol. Cell. 2007; 25: 207-217Abstract Full Text Full Text PDF PubMed Scopus (383) Google Scholar). the of HIF-1α the domain is involved with HSP90 and RACK1 interaction and regulation (11.Liu Y.V. Baek J.H. Zhang H. Diez R. Cole R.N. Semenza G.L. Mol. Cell. 2007; 25: 207-217Abstract Full Text Full Text PDF PubMed Scopus (383) Google Scholar, A. L.M. J. Biol. Chem. 2002; Full Text Full Text PDF PubMed Scopus Google we that the HIF-1α protein by SEPT9_v1 be a of a between RACK1 and SEPT9_v1 for HIF-1α binding. this we used PC-3 expressing SEPT9_v1 protein (PC-3-SEPT9_v1) and its expressing the empty vector PC-3 cells were with of the HSP90 17-AAG, a of The of HIF-1α protein by was in cells with cells under normoxic and hypoxic On the functional induced inhibition of HIF-1 transcriptional activity in cells with cells under normoxic Under hypoxia, also HIF-1 transcriptional activity by in cells with cells that SEPT9_v1 HIF-1α from a degradation mediated by the that SEPT9_v1 RACK1 binding to HIF-1α, HEK293 cells were with HIF-1α, or RACK1 for The of HIF-1α with RACK1 was in the of SEPT9_v1 with the of HIF-1α with SEPT9_v1 was also in the of RACK1 with HIF-1α protein expression was increased by SEPT9_v1 and by RACK1 and with 1). The HSP90 HIF-1α protein levels and to a in the of RACK1 and with 1). to SEPT9_v1 was associated with HIF-1α with and with SEPT9_v1 was able to HIF-1α from degradation induced by and RACK1 with In even in the of 17-AAG, the of SEPT9_v1 and RACK1 with HIF-1α was as by with and with as an of SEPT9_v1 as an of RACK1 with other to directly HIF-1α. RACK1 binds to SEPT9_v1 binds HIF-1α to degradation by RACK1 and of HIF-1α. SEPT9_v1 that SEPT9_v1 not HIF-1β (13.Amir S. Wang R. Matzkin H. Simons J.W. Mabjeesh N.J. Cancer Res. 2006; 66: 856-866Crossref PubMed Scopus (57) Google Scholar). A of is to other proteins W.J. J. Cell Sci. 2006; PubMed Scopus Google Scholar, M. Cell Biol. 2006; PubMed Scopus Google Scholar). SEPT9_v1 binds the domain of HIF-1α and the domain for with HIF-1β in to the we SEPT9_v1 HIF-1α in a that HIF-1β competes with PC-3 cells were transfected with SEPT9_v1 and were to an using HIF-1α of the that the of HIF-1β protein associated with HIF-1α protein in the of SEPT9_v1 was increased in the were also in HEK293 cells with HIF-1α and SEPT9_v1 not SEPT9_v1 not with HIF-1β to HIF-1α, HIF-1β is associated with HIF-1α in the of SEPT9_v1. is interaction between SEPT9_v1 and the that SEPT9_v1 has an cellular in SEPT9_v1 HIF-1α and the of SEPT9_v1 on HIF-1α degradation and on we PC-3 cells expressing specific to SEPT9_v1 (PC-3-shSEPT9_v1) and PC-3 cells expressing the empty vector (PC-3-Puro) SEPT9_v1 protein expression was by in cells with cells In induced degradation of HIF-1α with cells In with SEPT9_v1 also increased RACK1 binding to HIF-1α, in the of On the other SEPT9_v1 a interaction between HIF-1α and HIF-1β the from SEPT9_v1 and the of SEPT9_v1 on HIF-1α degradation by RACK1 as as the on In we of the of the septin family member, SEPT9_v1 in HIF-1 activation in prostate cancer cells. SEPT9_v1 as a HIF-1α that HIF-1α proteasomal degradation. a SEPT9_v1 HIF-1α levels. we that SEPT9_v1 to of HIF-1α with HIF-1β to a functional HIF-1 transcription on of the that to the aerobic activation of HIF-1 in cancer cells. The of SEPT9_v1 on HIF-1α to HSP90 in proteins and HIF-1α from proteasomal degradation (13.Amir S. Wang R. Matzkin H. Simons J.W. Mabjeesh N.J. Cancer Res. 2006; 66: 856-866Crossref PubMed Scopus (57) Google Scholar, N.J. Simons J.W. H. Cancer Res. 2002; Google Scholar, A. L.M. J. Biol. Chem. 2002; Full Text Full Text PDF PubMed Scopus Google Scholar, L. Chem. PubMed Scopus Google Scholar). HSP90 interacts with HIF-1α, but is not with HIF-1α into the E. D. G. M. J. 1999; PubMed Scopus Google Scholar). In SEPT9_v1 was shown to with HIF-1α in the (13.Amir S. Wang R. Matzkin H. Simons J.W. Mabjeesh N.J. Cancer Res. 2006; 66: 856-866Crossref PubMed Scopus (57) Google Scholar). We therefore that SEPT9_v1 has an in HIF-1α from ubiquitination and proteasomal degradation that in the J.L. R. Y. Poellinger L. Mol. Cell. Biol. 2006; PubMed Scopus Google Scholar). and of HIF-1α were critical for HSP90 binding E. D. G. M. J. 1999; PubMed Scopus Google Scholar, L. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, L. Cell Biochem. PubMed Scopus Google Scholar). We discovered that the domain but not the domain is for SEPT9_v1 binding HSP90 (11.Liu Y.V. Baek J.H. Zhang H. Diez R. Cole R.N. Semenza G.L. Mol. Cell. 2007; 25: 207-217Abstract Full Text Full Text PDF PubMed Scopus (383) Google Scholar, Y.V. Semenza G.L. Cell 2007; 6: PubMed Scopus Google Scholar) and SEPT9_v1 with RACK1 for binding HIF-1α. In in the of the HSP90 17-AAG, the interaction of HIF-1α with HSP90 is the of SEPT9_v1 with HIF-1α is leading to increased HIF-1α and and SEPT9_v1 protein levels were in the of 17-AAG, the interaction between HIF-1α and RACK1 becomes leading to increased HIF-1α degradation and that is a between the HSP90, and RACK1 involved in the of the transcriptional activation of HIF-1 as in On the other HSP90, which also binds L. Cell Biochem. PubMed Scopus Google SEPT9_v1 interacts specifically with HIF-1α is other of the conserved septin family be involved in the regulation of other We also that HIF-1α interaction with SEPT9_v1 is essential for HIF-1 activation. of the domain of which part of the GTPase was of HIF-1α-SEPT9_v1 complex and inhibiting HIF-1 transcriptional activity the for with high that with or the binding HIF-1α-SEPT9_v1 a new of HIF-1 as HSP90 have been previously L. Chem. PubMed Scopus Google Scholar). be to the of HSP90 with of HIF-1α-SEPT9_v1 interaction of HIF-1α. the of HIF-1α was not for the interaction with SEPT9_v1 the of HIF-1α to SEPT9_v1 under hypoxia was (13.Amir S. Wang R. Matzkin H. Simons J.W. Mabjeesh N.J. Cancer Res. 2006; 66: 856-866Crossref PubMed Scopus (57) Google Scholar). for this interaction is that SEPT9_v1 is by HIF-1β under is to that HIF-1β and to domain of HIF-1α of In the of SEPT9_v1 be that the of HIF-1β associated with HIF-1α be In the of HIF-1α binds to HIF-1β in the of SEPT9_v1 and SEPT9_v1 levels are are with that as proteins for critical cellular W.J. J. Cell Sci. 2006; PubMed Scopus Google Scholar, M. Cell Biol. 2006; PubMed Scopus Google Scholar). The in to HIF-1α, SEPT9_v1 also to the interaction with HIF-1β for and of functional We that SEPT9_v1 is involved in HIF-1α by of the of RACK1 in degradation of HIF-1α levels. was discovered as a fusion of or in and was or M. N.J. Sci. S. A. 1999; PubMed Scopus Google Scholar, H. K. M. M. Y. Cancer Res. 1999; Google Scholar). that SEPT9_v1 therefore be in cells and et al. M. G. PubMed Scopus Google Scholar) found of in a of human (e.g. and human and human cell we described of SEPT9_v1 protein in multiple human cancer cells (e.g. and which was by and was with to (15.Amir S. Mabjeesh N.J. Cancer Biol. Ther. 2007; 6: 1926-1931Crossref PubMed Scopus (32) Google Scholar). Gonzalez et al. (14.Gonzalez M.E. Peterson E.A. Privette L.M. Loffreda-Wren J.L. Kalikin L.M. Petty E.M. Cancer Res. 2007; 67: 8554-8564Crossref PubMed Scopus (59) Google Scholar) recently have also found that SEPT9_v1 is highly expressed in a of human breast by functional in human breast cells that SEPT9_v1 growth promotes cell increases in by of and stimulates associated with in human breast cells (14.Gonzalez M.E. Peterson E.A. Privette L.M. Loffreda-Wren J.L. Kalikin L.M. Petty E.M. Cancer Res. 2007; 67: 8554-8564Crossref PubMed Scopus (59) Google Scholar). increases in tumor and be to the SEPT9_v1 of We and have described of HIF-1α in human breast cancer in and in H. E. M. D.A. D. P. Semenza G.L. Simons J.W. Cancer Res. 1999; Google Scholar, E. P. K. P.C. Semenza G.L. Mol. Cell. Biol. 2001; PubMed Scopus Google Scholar, R. H. Semenza G.L. Simons J.W. P.J. E. J. Cancer 2001; PubMed Scopus Google Scholar). HIF-1 is also associated with and in J. G. L. P. R. K. Cancer Res. Google Scholar, S. Hirota K. M. Cancer Res. 2007; 67: PubMed Scopus Google Scholar). be of to SEPT9_v1 is to the of HIF-1α in HIF-1α-SEPT9_v1 binding was discovered in human prostate cancer cells (13.Amir S. Wang R. Matzkin H. Simons J.W. Mabjeesh N.J. Cancer Res. 2006; 66: 856-866Crossref PubMed Scopus (57) Google Scholar). et al. Y. M. S. A. Y. L.A. J. S. D. S. K. L.A. E. M. J. Cancer 2008; PubMed Scopus Google Scholar) on the expression for prostate with the fusion between the and a member of transcription factor identified an expression that fusion prostate cancer as a a expression in with the Y. M. S. A. Y. L.A. J. S. D. S. K. L.A. E. M. J. Cancer 2008; PubMed Scopus Google Scholar). with the fusion to have a other prostate K. S. Y. J.M. Y. L.A. 2007; PubMed Scopus Google Scholar). is in prostate cancer that part of the of is SEPT9_v1 activation of HIF-1α in prostate the of SEPT9_v1 RACK1 on HIF-1α have not been previously to SEPT9_v1 the of other HSP90 additional novel to the functional of SEPT9_v1. of SEPT9_v1 protein levels in in prostate cancer and other human to be of in the of SEPT9_v1 in the of HIF-1 in human We the critical of

References

31